The dysregulated expression of PD-L1 in cancer has been attributed to the oncogenic activation of multiple signaling pathways, including JAK/STAT, PI3K/Akt/mTOR, MEK/ERK, and Jun/AP-1 which can either act independently or synergistically to regulate PD-L1 expression (273–275). Here, SOAT1 is linked to cancer.